. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: J Am Acad Dermatol. 2021 Jan 23;86(5):1092–1101. doi: 10.1016/j.jaad.2021.01.059

Table II.

Suggested screening methods and frequency for comorbid conditions in HS

Comorbidity in HS	Screening method	Suggested frequency

Screening performed by dermatologist using physical examination; manage if positive screening result
Acne vulgaris/conglobata	Physical examination of face and trunk	Annual
Dissecting cellulitis of scalp	Physical examination of scalp	Annual
Pilonidal disease	Physical examination of sacral region	Annual
Pyoderma gangrenosum	Physical examination of ulcerations	With presence of cutaneous ulcerations
Down syndrome	Physical examination of patients with Down syndrome for findings suggestive of HS	Annual
Screening performed by dermatologist using screening question; refer for management with positive screening result
Tobacco smoking	Screening question: “In the past year, how often have you used tobacco products?”⁵	Annual
Inflammatory bowel disease	Screening question: “Have you had abdominal pain at least 3 times a week for at least 4 weeks, bloody stools, diarrhea (more than 3 bowel movements daily) for 7 consecutive days, or been awoken from sleep because of abdominal pain or diarrhea?”⁶	Annual
Spondyloarthritis	Screening question: “Do you have joint pain or stiffness that is worse first thing in the morning or after a period of inactivity and gets better as the day goes on?”	Annual
Sexual dysfunction	Screening question: “Have you been sexually active in the past 6 months? Do you or your partner have any sexual difficulties, such as your interest level or intercourse-related pain?”	Annual
Screenings referred to primary care or other specialty for screening and management
Obesity	Measurement of height and weight with calculation of body mass index⁷	Determined by physician to whom patient is referred
Depression	PHQ-2 and PHQ-9⁸	Determined by physician to whom patient is referred
Generalized anxiety disorder	GAD-7⁹	Determined by physician to whom patient is referred
Suicidality	Item 9 of the PHQ-9 assessing thoughts of self-harm¹⁰	Determined by physician to whom patient is referred
Substance use disorder	Alcohol: AUDIT-C questionnaire¹¹ Opioid Risk Tool¹²	Determined by physician to whom patient is referred
Polycystic ovary syndrome	Rotterdam criteria with ≥2 of the following: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries on transvaginal ultrasonography.¹³	Determined by physician to whom patient is referred
Hypertension	Blood pressure measurement⁷	Determined by physician to whom patient is referred
Dyslipidemia	Fasting lipid panel⁷	Determined by physician to whom patient is referred
Diabetes mellitus	Glycated hemoglobin or fasting blood glucose⁷	Determined by physician to whom patient is referred
Metabolic syndrome	Abnormality in ≥3 of the following: blood pressure measurement, fasting triglyceride, fasting HDL, fasting blood glucose, waist circumference measurement⁷	Determined by physician to whom patient is referred
Cardiovascular disease	Anthropometric measurements, waist circumference measurement, blood pressure measurement, fasting lipid panel, fasting blood glucose, assessment of tobacco use, physical activity and diet⁷	Determined by physician to whom patient is referred

AUDIT, Alcohol Use Disorders Identification Test; GAD, generalized anxiety disorder; HDL, high-density lipoproteins; HS, hidradenitis suppurativa; PHQ, Patient Health Questionnaire.